Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rSjP40
- Development stage
- Preclinical
- Lead developer
- Nantong University
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Topical
01
Overview
rSjP40 (recombinant Schistosoma japonicum protein 40) is a recombinant egg antigen protein derived from the helminth parasite *Schistosoma japonicum*. It is being investigated for its therapeutic potential in treating liver fibrosis, promoting wound healing, and preventing graft rejection. Mechanistically, rSjP40 acts as an agonist of CD36 (platelet glycoprotein 4) on hepatocytes, activating the AMP-activated protein kinase (AMPK) pathway and suppressing lipogenesis. In hepatic stellate cells (HSCs), rSjP40 inhibits activation and collagen deposition by suppressing Toll-like receptor 4 (TLR4) signaling, downregulating ATF3 expression via upregulation of microRNA-494-3p, and promoting cellular senescence through the STAT3/p53/p21 and SKP2/p27 pathways. Additionally, rSjP40 enhances wound healing by regulating macrophage polarization and promoting tissue regeneration.
- Other names
- recombinant Schistosoma japonicum egg antigen p40recombinant Schistosoma japonicum egg protein P40recombinant Schistosoma japonicum protein 40rSjp40rSjp-40rSjp 40SjP40SjP-40SjP 40
02
Targets
CD36 (CD36 antigen)
Beyond the preview
Go deeper on rSjP40.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rSjP40.